| Literature DB >> 32784836 |
Sára Zsigrai1, Alexandra Kalmár1,2, Zsófia B Nagy1, Barbara K Barták1, Gábor Valcz1,2, Krisztina A Szigeti1, Orsolya Galamb1,2, Titanilla Dankó3, Anna Sebestyén3, Gábor Barna3, Vanessza Szabó3, Orsolya Pipek4, Anna Medgyes-Horváth4, István Csabai4, Zsolt Tulassay2,5, Péter Igaz1,2, István Takács1, Béla Molnár1,2.
Abstract
Global DNA hypomethylation is a characteristic feature of colorectal carcinoma (CRC). The tumor inhibitory effect of S-adenosylmethionine (SAM) methyl donor has been described in certain cancers including CRC. However, the molecular impact of SAM treatment on CRC cell lines with distinct genetic features has not been evaluated comprehensively. HT-29 and SW480 cells were treated with 0.5 and 1 mmol/L SAM for 48 h followed by cell proliferation measurements, whole-genome transcriptome and methylome analyses, DNA stability assessments and exome sequencing. SAM reduced cell number and increased senescence by causing S phase arrest, besides, multiple EMT-related genes (e.g., TGFB1) were downregulated in both cell lines. Alteration in the global DNA methylation level was not observed, but certain methylation changes in gene promoters were detected. SAM-induced γ-H2AX elevation could be associated with activated DNA repair pathway showing upregulated gene expression (e.g., HUS1). Remarkable genomic stability elevation, namely, decreased micronucleus number and comet tail length was observed only in SW480 after treatment. SAM has the potential to induce senescence, DNA repair, genome stability and to reduce CRC progression. However, the different therapeutic responses of HT-29 and SW480 to SAM emphasize the importance of the molecular characterization of CRC cases prior to methyl donor supplementation.Entities:
Keywords: DNA methylation; EMT; S-adenosylmethionine; cancer therapy; colorectal cancer; epigenetics; genomic stability
Mesh:
Substances:
Year: 2020 PMID: 32784836 PMCID: PMC7464653 DOI: 10.3390/cells9081864
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1(a) Cell proliferation of HT-29 and SW480 cells were analyzed with SRB (sulforhodamine B) assay. The median of control (0 mmol/L S-adenosylmethionine (SAM)) cells was taken as 100% and the average results of the treatment groups (0.5 mmol/L; 1 mmol/L SAM) were compared to this value (** p ≤ 0.005, *** p ≤ 0.0005, and **** p ≤ 0.0001). (b) Cell cycle alterations were detected with FACS (fluorescence-activated cell sorting) in HT-29 and SW480 cells. Left: Percentage of cell distribution in different phases of the cell cycle (* p ≤ 0.05, ** p ≤ 0.005). Right: Representative histograms about each treatment conditions. Dip: diploid.
Figure 2Expression analysis of genes included (a) in the gene set compiled by Bakhoum et al. [30] and (b) in the epithelial–mesenchymal transition (EMT) pathway comparing control (0 mmol/L) and SAM-treated (0.5 mmol/L; 1 mmol/L) HT-29 (left) and SW480 (right) cells. Transcripts that show significant (p ≤ 0.05) alterations with a fold change (FC) ≥ |1.4| in the comparison of 0 and 1 mmol/L SAM treatment were illustrated on heatmaps. Columns are referred to the applied SAM concentration and each row represents a gene transcript probe set on the HTA 2.0 microarray platform (Affymetrix). Green color symbolizes downregulation, while red means increased expression.
Figure 3(a) Global DNA methylation of control (0 mmol/L) and SAM-treated (0.5 mmol/L; 1 mmol/L) HT-29 (left) and SW480 (right) cells were analyzed by pyrosequencing. DNA methylation status was represented as the average methylation level of three individual CpGs of LINE-1 retrotransposon. (b) Promoter-specific methylation of SAM-treated HT-29 (left) and SW480 (right) cells was detected with EPIC BeadChip array. The number of all hypo- and hypermethylated probes located in promoter regions of CpG islands are visualized. (c) The top 10 hypo- and hypermethylated probes with the largest absolute mean methylation difference (Δβ) between SAM-treated (0.5 mmol/L; 1 mmol/L) and control (0 mmol/L) HT-29 and SW480 cells were analyzed by EPIC BeadChip array. Funct. reg.: functional region.
Figure 4(a) Left: Concentration of γ-H2AX was determined with ELISA. Right: Representative immunofluorescence staining images of γ-H2AX intensity following SAM treatment were captured. (b) Left: Micronucleus scoring was performed on the slides stained with DAPI and anti-γ-H2AX (* p ≤ 0.05). Right: Arrows indicate representative micronuclei with γ-H2AX positivity. (c) Left: Percentage of DNA in the tail was referred as comet tail DNA % (* p ≤ 0.05). Right: Characteristic comets are visualized following SAM treatment.
Figure 5Expression analysis of genes included (a) in the DNA damage response pathway and (b) in histone modification gene set in control (0 mmol/L) and SAM-treated (0.5 mmol/L; 1 mmol/L) HT-29 (left) and SW480 (right) cells. Transcripts showing significant (p ≤ 0.05) alterations with a FC ≥ |1.4| in the comparison of 0 and 1 mmol/L SAM treatment were illustrated on heatmaps. Columns are referred to the applied SAM concentration and each row represents a gene transcript probe-set on the HTA 2.0 microarray platform (Affymetrix). Green color symbolizes downregulation, while red means increased expression.
Figure 6Fragment–length distribution of cell-free DNA isolated from the media of HT-29 and SW480 cells was detected with BioAnalyzer. Electropherograms represent a data plot of size in base pairs (bp) versus fluorescence (FU). Average DNA concentrations were measured with Qubit 1.0 fluorometer. Av. conc.: average concentration.
Figure 7Mutation profile of HT-29 and SW480 cell lines was analyzed by exome sequencing. Intronic variants were excluded, and mutated genes considered as likely oncogenic on the basis of the OnkoKB database were shown. Grey color indicates gene mutation.